Short Interval SBRT After Surgery for Spine Metastases
This study is looking at a new way to deliver radiation therapy called Stereotactic Body Radiation Therapy (SBRT) for people who have had surgery for spine metastases (cancer that has spread to the spine). Current guidelines suggest waiting 2-4 weeks after surgery for SBRT, which can cause delays. This study will investigate giving SBRT sooner, within a single hospital stay after surgery, to see if it reduces wound complications and improves how well the treatment controls the tumor. You would receive SBRT, undergo imaging like Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), and complete questionnaires about your health and quality of life. The main goal is to see how well this short-interval SBRT controls the tumor at 6 months. We are looking for 50 participants aged 18 and older who have metastatic cancer confirmed by a doctor and are considered suitable for postoperative SBRT. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 50 participants. It will first look at safety and then investigate local tumor control.
- What's involved
- You would receive SBRT 3-14 days after surgery, undergo CT and MRI imaging, and complete health-related questionnaires. You would have follow-up visits at 1, 6, and 12 months after SBRT.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants are followed up for at least 12 months after SBRT, or until removal from the study or death.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases
At a glance
Conditions
NCT07346170
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Francisco
San Francisco, Californiastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Steve Braunstein, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Local Control (LC) Rate6 months after SBRT
Local control (LC) is defined as the time from SBRT radiotherapy to metastatic lesions (event) within the SBRT treatment field with stable or decreased size as measured by a board-certified radiologist on follow-up imaging. Participants without any documented events or death will be censored. Estimates and confidence interval will be reported using the Kaplan Meier method.